PLA2G7 and atherosclerosis: Lead optimization resulted in the development of darapladib (27, Lp-PLA2 IC50 = 0.25 nM; Figure 6) as a clinical candidate and is the first agent developed as an Lp-PLA2 inhibitor to treat atherosclerosis and associated cardiovascular diseases [70,71].